The Pfizer/BioNTech Vaccine UK Product Info & VRBPAC Briefing

The United Kingdom wins the prize for being the most reckless nation on the planet for being the first to authorize one of the rushed, experimental vaccines for use by its citizens, despite the growing formal opposition by scientists and doctors who are increasingly filing petitions and papers about their concerns. Here is one example:

Dr. Leonard Horowitz Files COVID-19 Vaccine Lawsuit to Block FDA’s Approval

Not actually “vaccines” in the traditional sense, but “genetic therapies” according to the companies, the court is asked to enjoin the government from approving and distributing the injections due to neglected genetic safety science and inadequate testing.“

Genetics (specified analyses) are not evaluated in this study,” the Pfizer Protocol admitted. The same is true for the Moderna vaccine.

Dr. Horowitz’s 84-page lawsuit holds Pfizer and Moderna vaccine advertisers and distributors accountable for false advertising of the vaccines’ safety under Florida’s unfair and deceptive trade act and whistleblower law. Eight claims are brought by the whistleblowing doctor and litigator who has asked the court for a number of “remedies” besides the injunction.

One of Horowitz’s remedies would require Defendants to supplement their COVID-19 vaccine trials to assess the risks of genetic alterations to human DNA and viral genes.

“The injunction should require Defendants to . . . assess the risks of genetic ‘reassortments’ of latent DNA and RNA tumor viruses in medically or immune compromised people,” the lawsuit pleads.

“The injunction should require the federal government to suspend its acquisition of the Defendants’ COVID-19 vaccines until such a time as the aforementioned safety concerns are studied and resolved by supplemental trials, the results of which are candidly published,” the doctor added . . . read the rest of the article HERE.


This is a multidose vial and must be diluted before use. 1 vial (0.45 mL) contains 5 doses of 30 microgramsof BNT162b2 RNA (embedded in lipid nanoparticles).

COVID-19 mRNA Vaccine BNT162b2 is highly purified single-stranded, 5’-capped messenger RNA (mRNA) produced by cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2.
List of excipients 
ALC-0315 = (4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate),
ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 
potassium chloride,
potassium dihydrogen phosphate, 
sodium chloride,
disodium hydrogen phosphate dihydrate, sucrose,
water for injections 


These are preliminary findings, showing only what was reported during the first weeks of the study, up until a set number of participants experienced illness symptoms and then had a PCR positive test, a week or more after getting a second dose. This is still very much an experimental and untested product.

The most frequent adverse reactions in participants 16 years of age and older were pain at the injection site (> 80%), fatigue (> 60%), headache (> 50%), myalgia (> 30%), chills (> 30%), arthralgia (> 20%) and pyrexia (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. If required, symptomatic treatment with analgesic and/or anti-pyretic medicinal products (e.g. paracetamol-containing products) may be used. 

Adverse reactions from clinical studies

Adverse reactions reported in clinical studies are listed in this section per MedDRA system organ class, indecreasing order of frequency and seriousness. The frequency is defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from available data).

Blood and lymphatic system disorders 
Uncommon: Lymphadenopathy 

Nervous system disorders
Very common: Headache 

Musculoskeletal and connective tissue disorders 

Very common: Arthralgia; myalgia 

General disorders and administration site conditions 

Very common: Injection-site pain; fatigue; chills; pyrexia 
Common: Redness at injection site; injection site swelling Uncommon: Malaise 

Gastrointestinal disorders 
Common Nausea 

READ the full EU document HERE.

Pfizer submitted a briefing to the U.S. Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting for December 10, 2020.

READ the full Briefing HERE.

Print Friendly, PDF & Email

Like what you learned? Subscribe to our Feed to get email notice of new posts.

Get new posts by email: